Literature DB >> 25986571

Conformational Dynamics in FKBP Domains: Relevance to Molecular Signaling and Drug Design.

David M LeMaster, Griselda Hernandez1.   

Abstract

Among the 22 FKBP domains in the human genome, FKBP12.6 and the first FKBP domains (FK1) of FKBP51 and FKBP52 are evolutionarily and structurally most similar to the archetypical FKBP12. As such, the development of inhibitors with selectivity among these four FKBP domains poses a significant challenge for structure-based design. The pleiotropic effects of these FKBP domains in a range of signaling processes such as the regulation of ryanodine receptor calcium channels by FKBP12 and FKBP12.6 and steroid receptor regulation by the FK1 domains of FKBP51 and FKBP52 amply justify the efforts to develop selective therapies. In contrast to their close structural similarities, these four FKBP domains exhibit a substantial diversity in their conformational flexibility. A number of distinct conformational transitions have been characterized for FKBP12 spanning timeframes from 20 s to 10 ns and in each case these dynamics have been shown to markedly differ from the conformational behavior for one or more of the other three FKBP domains. Protein flexibilitybased inhibitor design could draw upon the transitions that are significantly populated in only one of the targeted proteins. Both the similarities and differences among these four proteins valuably inform the understanding of how dynamical effects propagate across the FKBP domains as well as potentially how such intramolecular transitions might couple to the larger scale transitions that are central to the signaling complexes in which these FKBP domains function.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25986571      PMCID: PMC5592401          DOI: 10.2174/1874467208666150519113146

Source DB:  PubMed          Journal:  Curr Mol Pharmacol        ISSN: 1874-4672            Impact factor:   3.339


  103 in total

1.  The prospect of FKBP51 as a drug target.

Authors:  Mathias V Schmidt; Marcelo Paez-Pereda; Florian Holsboer; Felix Hausch
Journal:  ChemMedChem       Date:  2012-05-13       Impact factor: 3.466

2.  Redesigning an FKBP-ligand interface to generate chemical dimerizers with novel specificity.

Authors:  T Clackson; W Yang; L W Rozamus; M Hatada; J F Amara; C T Rollins; L F Stevenson; S R Magari; S A Wood; N L Courage; X Lu; F Cerasoli; M Gilman; D A Holt
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-01       Impact factor: 11.205

3.  Role of leaky neuronal ryanodine receptors in stress-induced cognitive dysfunction.

Authors:  Xiaoping Liu; Matthew J Betzenhauser; Steve Reiken; Albano C Meli; Wenjun Xie; Bi-Xing Chen; Ottavio Arancio; Andrew R Marks
Journal:  Cell       Date:  2012-08-31       Impact factor: 41.582

4.  Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast.

Authors:  J Heitman; N R Movva; M N Hall
Journal:  Science       Date:  1991-08-23       Impact factor: 47.728

5.  A rapid, reversible, and tunable method to regulate protein function in living cells using synthetic small molecules.

Authors:  Laura A Banaszynski; Ling-Chun Chen; Lystranne A Maynard-Smith; A G Lisa Ooi; Thomas J Wandless
Journal:  Cell       Date:  2006-09-08       Impact factor: 41.582

6.  A role for FKBP52 in Tau protein function.

Authors:  Béatrice Chambraud; Elodie Sardin; Julien Giustiniani; Omar Dounane; Michael Schumacher; Michel Goedert; Etienne-Emile Baulieu
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-25       Impact factor: 11.205

7.  Role of FK506-binding protein 51 in the control of apoptosis of irradiated melanoma cells.

Authors:  S Romano; A D'Angelillo; R Pacelli; S Staibano; E De Luna; R Bisogni; E-L Eskelinen; M Mascolo; G Calì; C Arra; M F Romano
Journal:  Cell Death Differ       Date:  2010-01       Impact factor: 15.828

8.  FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt.

Authors:  Huadong Pei; Liang Li; Brooke L Fridley; Gregory D Jenkins; Krishna R Kalari; Wilma Lingle; Gloria Petersen; Zhenkun Lou; Liewei Wang
Journal:  Cancer Cell       Date:  2009-09-08       Impact factor: 31.743

9.  Statistical allosteric coupling to the active site indole ring flip equilibria in the FK506-binding domain.

Authors:  Janet S Anderson; Sourajit M Mustafi; Griselda Hernández; David M LeMaster
Journal:  Biophys Chem       Date:  2014-06-24       Impact factor: 2.352

10.  A peptidyl-prolyl isomerase, FKBP12, accumulates in Alzheimer neurofibrillary tangles.

Authors:  Hisato Sugata; Kazuhiko Matsuo; Taisuke Nakagawa; Mikiko Takahashi; Hideyuki Mukai; Yoshitaka Ono; Kiyoshi Maeda; Haruhiko Akiyama; Toshio Kawamata
Journal:  Neurosci Lett       Date:  2009-05-03       Impact factor: 3.046

View more
  6 in total

1.  Quantifying protein dynamics in the ps-ns time regime by NMR relaxation.

Authors:  Griselda Hernández; David M LeMaster
Journal:  J Biomol NMR       Date:  2016-10-12       Impact factor: 2.835

2.  FKBP51 Null Mice Are Resistant to Diet-Induced Obesity and the PPARγ Agonist Rosiglitazone.

Authors:  Lance A Stechschulte; Bin Qiu; Manya Warrier; Terry D Hinds; Man Zhang; Hao Gu; Yuxue Xu; Saja S Khuder; Lucia Russo; Sonia M Najjar; Beata Lecka-Czernik; Weidong Yong; Edwin R Sanchez
Journal:  Endocrinology       Date:  2016-07-21       Impact factor: 4.736

Review 3.  Imbalances in the Hsp90 Chaperone Machinery: Implications for Tauopathies.

Authors:  Lindsey B Shelton; John Koren; Laura J Blair
Journal:  Front Neurosci       Date:  2017-12-22       Impact factor: 4.677

Review 4.  The FKBP51 Glucocorticoid Receptor Co-Chaperone: Regulation, Function, and Implications in Health and Disease.

Authors:  Gabriel R Fries; Nils C Gassen; Theo Rein
Journal:  Int J Mol Sci       Date:  2017-12-05       Impact factor: 5.923

Review 5.  The Many Faces of FKBP51.

Authors:  Andreas Hähle; Stephanie Merz; Christian Meyners; Felix Hausch
Journal:  Biomolecules       Date:  2019-01-21

Review 6.  Hsp90 and Its Co-Chaperones in Neurodegenerative Diseases.

Authors:  Anastasiia Bohush; Paweł Bieganowski; Anna Filipek
Journal:  Int J Mol Sci       Date:  2019-10-09       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.